These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2671502)

  • 1. Comparison of polyclonal antibody sera for early prophylaxis following cardiac transplantation.
    Bolling SF; Stirling MC; Miska P; Deeb GM
    J Surg Res; 1989 Oct; 47(4):292-6. PubMed ID: 2671502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
    Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
    Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of low-dose steroids and prophylactic monoclonal versus polyclonal antibodies on acute rejection in cyclosporine- and azathioprine-immunosuppressed cardiac allografts.
    Laufer G; Laczkovics A; Wollenek G; Schreiner W; Sochor H; Holzinger C; Buchelt M; Fasol R; Wolner E
    J Heart Transplant; 1989; 8(3):253-61. PubMed ID: 2661776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of pretransfusion/azathioprine/prednisone versus cyclosporine/prednisone immunosuppression in cardiac transplant recipients: preliminary results.
    Barnhart GR; Hastillo A; Goldman MH; Szentpetery S; Wolfgang TC; Mohanakumar T; Katz MR; Rider S; Hanrahan J; Lower RR
    Circulation; 1985 Sep; 72(3 Pt 2):II227-30. PubMed ID: 3896555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE; Fryd DS; Strand MH; Canafax DM; Ascher NL; Payne WD; Simmons RL; Najarian JS
    Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation.
    Kupin WL; Venkatachalam KK; Oh HK; Dienst S; Levin NW
    Transplantation; 1985 Dec; 40(6):601-4. PubMed ID: 3907029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection.
    Deeb GM; Bolling SF; Steimle CN; Dawe JE; McKay AL; Richardson AM
    Transplantation; 1991 Jan; 51(1):180-3. PubMed ID: 1824803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunosuppression therapy following heart transplantation: pretransfusion/azathioprine/ATG/prednisone versus cyclosporine/prednisone.
    Barnhart GR; Goldman MH; Hastillo A; Szentpetery S; Wolfgang T; Thompson J; Mohanakumar T; Katz MR; Rider S; Hanrahan J
    J Heart Transplant; 1985; 4(4):381-4. PubMed ID: 3916511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.
    Brennan DC; Flavin K; Lowell JA; Howard TK; Shenoy S; Burgess S; Dolan S; Kano JM; Mahon M; Schnitzler MA; Woodward R; Irish W; Singer GG
    Transplantation; 1999 Apr; 67(7):1011-8. PubMed ID: 10221486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
    Johnson CP; Simmons RL; Sutherland DE; Canafax DM; Ascher NL; Payne WD; Flick B; Najarian JS; Fryd DS
    Transplantation; 1988 Feb; 45(2):380-5. PubMed ID: 3278431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.